UNC0638 - G9a HMTase Inhibitor. CAS# 1255580-76-7 yltransferase JNJ-42041935 is a new pharmacological

JNJ-42041935 is a new pharmacological tool

Su-11274 inhibits HGF-dependent phosphorylation of Met as well as HGF-dependent cell proliferation and motility with an IC50 of 1-1

It has >100-fold selectivity over other methyltransferases tested

G-749 retained its inhibitory potency in various drug-resistance milieus such as patient plasma

[Epub ahead of print] PubMed PMID: 20502937

UNC0638 - G9a HMTase Inhibitor. CAS# 1255580-76-7 yltransferase JNJ-42041935 is a new pharmacologicalUNC0638, CAS No. 1255580 76 7, is a potent, selective and cell permeable G9a and GLP inhibitor, with a toxicity function ratio of >100, compared to <6 for BIX01294. UNC0638 inhibits G9a HMTase with an IC50 ~15 nM and GLP, a closely related H3K9 HMTase, with an IC50~19 nM, but is more than 10, 000 fold selective over other epigenetic targets. G9a (EHMT2) and GLP (EHMT1) catalyze the mono and dimethylation of lysine 9 of histone 3 (H3K9) and other non